Sean Parker - Concepedia

Author

Sean Parker

King's College London ORCID

Also Known As

A Lea, A. Melville, C. Pariante, Catherine Oliver, H Parfrey, H. Parfrey, L Ingram, M. Pareek, S M Parker, S Parker

Publications

4.2K

Citations

H-Index

Concepts

All Affiliations

King's College London Queen's University Belfast North Tyneside General Hospital University of Manchester Newcastle University

About

Sean Parker is an author at King's College London specializing in medicine, asthma, and pulmonary disease.

Top Concepts

#	Concept	H-Index	Publications	Citations
1	Medicine	10	10	1.1K
2	Health Sciences	2	2	50
3	Public Health	2	2	87
4	Cell Biology	2	2	132
5	Cellular Physiology	1	1	115

Sean Parker

Publications

3.1K

Citations

H-Index

Page 1

	Year	Citations
Convalescent plasma in patients admitted to hospital with COVID-19 (RECOVERY): a randomised controlled, open-label, platform trial Obbina Abani, Ali Abbas, Fatima Abbas, The Lancet	2021	516
Clinical characteristics with inflammation profiling of long COVID and association with 1-year recovery following hospitalisation in the UK: a prospective observational study Rachael A Evans, Olivia C. Leavy, Matthew Richardson, The Lancet Respiratory Medicine	2022	407
Casirivimab and imdevimab in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial Obbina Abani, Ali Abbas, Fatima Abbas, The Lancet Covid-19 PandemicAntiviral TherapyClinical TrialsPlatform TrialMedicine	2022	382
Aspirin in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial Obbina Abani, Ali Abbas, Fatima Abbas, The Lancet	2021	289
A worldwide survey of chronic cough: a manifestation of enhanced somatosensory response Alyn H. Morice, Adam D Jakes, Shoaib Faruqi, European Respiratory Journal AsthmaInhaled CapsaicinPulmonary CareChronic CoughCough Reflex Sensitivity	2014	272
Gefapixant, a P2X3 receptor antagonist, for the treatment of refractory or unexplained chronic cough: a randomised, double-blind, controlled, parallel-group, phase 2b trial John A. Smith, Michael M. Kitt, Alyn H. Morice, The Lancet Respiratory Medicine AsthmaPulmonary CarePhase 2BPharmacologyUnexplained Chronic Cough	2020	216
Physiotherapy, and speech and language therapy intervention for patients with refractory chronic cough: a multicentre randomised control trial Sarah Chamberlain, Rachel Garrod, Lynne Clark, Thorax	2016	187
Epithelial to mesenchymal transition (EMT) and airway remodelling after human lung transplantation Lee A. Borthwick, Sean Parker, K.A. Brougham, Thorax	2009	135
Free radical generation induces epithelial-to-mesenchymal transition in lung epithelium via a TGF-β1-dependent mechanism Marta R. Gorowiec, Lee A. Borthwick, Sean Parker, Free Radical Biology and Medicine Epithelial-mesenchymal TransitionTgf-β1-dependent MechanismDevelopmental BiologyTissue DevelopmentLung Epithelium	2012	115
Eliapixant (BAY 1817080), a P2X3 receptor antagonist, in refractory chronic cough: a randomised, placebo-controlled, crossover phase 2a study Alyn H. Morice, John A. Smith, Lorcan McGarvey, European Respiratory Journal	2021	94

Page 1